National Cancer Institute (NCI) clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-11
What changed in the last 30 days
110 trials changed in the last 30 days: 1 stopped, 42 with notable changes, 67 with minor changes only.
- Stopped: Tazemetostat in Combination With Topotecan and Pembrolizumab · Recurrent Small Cell Lung Cancer Trial terminated
- Notable: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma Primary completion pushed from Dec 1, 2026 to Aug 12, 2027
- Minor: Acalabrutinib With DA-EPOCH-R or R-CHOP · Untreated Diffuse Large B-cell Lymphoma Primary completion pushed from May 31, 2027 to Oct 12, 2027
- Minor: IL-12 Genetically Engineered Myeloid Cells · Relapsed, Refractory Solid Tumors Start date changed from estimate of Nov 11, 2026 to Nov 4, 2026
- Notable: Selumetinib in Treating Young · Recurrent or Refractory Low Grade Glioma Primary endpoint(s) modified
- Notable: Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Start date pushed from Oct 30, 2026 to Dec 30, 2026
- Minor: Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy Trial status changed: Suspended → Completed
- Minor: Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Trial sites expanded: 305 → 309 locations
- Minor: Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib · High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Trial sites expanded: 248 → 258 locations
- Minor: Different Treatment Lengths for Venetoclax · Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Trial sites expanded: 59 → 64 locations
- Minor: Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Trial sites expanded: 133 → 145 locations
- Minor: Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Trial sites expanded: 19 → 22 locations
- Minor: Measuring the Effects of Talazoparib · Advanced Cancer and DNA Repair Variations Study completion pushed from Jul 27, 2027 to Oct 22, 2027
- Minor: Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride · Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Study completion pushed from Oct 22, 2026 to Nov 3, 2027
- Notable: Nivolumab in Combination With Chemo-Immunotherapy · Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
- Notable: Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Primary and study completion pushed from Nov 3, 2026 to May 3, 2027
- Notable: Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant Primary completion pushed from Dec 1, 2027 to Dec 1, 2030
- Notable: Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy · Locally Advanced Pancreatic Cancer Trial status changed: Suspended → Active, Not Recruiting
- Minor: Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung Trial sites expanded: 263 → 266 locations
- Minor: Immunotherapy After Surgery · No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial Trial sites expanded: 280 → 284 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-04 | NCT07914855 Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer | Phase 2 | Not Yet Recruiting |
| 2026-10-29 | NCT07902921 STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic… | Phase 1/2 | Not Yet Recruiting |
| 2026-10-23 | NCT07891286 Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children… | Phase 2 | Not Yet Recruiting |
Active trials by phase
| Early Phase 1 | 1 | |
| Phase 1 | 162 | |
| Phase 1/2 | 79 | |
| Phase 2 | 316 | |
| Phase 2/3 | 17 | |
| Phase 3 | 80 | |
| Phase 4 | 3 |
Not charted: 124 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 50
Leukemia (95) · Lung Cancer (80) · Non-Hodgkin Lymphoma (70) · Sarcoma (67) · Breast Cancer (57) · Multiple Myeloma (52) · Colorectal Cancer (50) · Ovarian Cancer (50) · Non-Small Cell Lung Cancer (NSCLC) (47) · Head & Neck Cancer (46)
Get alerts when National Cancer Institute (NCI)'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.